Published on
15:37 GMT
Sanofi's venglustat granted new promising status
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Sanofi's experimental drug venglustat for the treatment of neurological manifestations of Gaucher disease type 3 (GD3). This decision is based on promising …
Source:
Market Screener
-
Neutral
)
